Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05154942
Other study ID # 20211129
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 15, 2021
Est. completion date November 15, 2023

Study information

Verified date November 2021
Source Shanghai Yueyang Integrated Medicine Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Preliminary studies have shown that before giving combined acupuncture and medicine anesthesia, electroacupuncture (EA) needs to be started three days before in order to produce a sequential effect. In combined acupuncture and drug anesthesia, the core goal is to use acupuncture to reduce the insufficiency of anesthetics in terms of analgesia, sedation, stable circulation, and protection of organs. However, the mechanism of action behind this combination has not yet been changed. The pharmacodynamics or pharmacokinetics has been convincingly explained, or the degree of recognition is not high, such as whether acupuncture has a specific target in the body, if there is a specific target, where the effect target is located ? Will it affect the metabolic enzymes and will it further affect the efficacy or toxicity of the drugs metabolized by the metabolic enzymes? What effect will it have on the pharmacokinetic mechanism? Given that it may involve complex pharmacodynamics and pharmacokinetic mechanisms, this study will first use doxofylline (DOXO) as a probe to study and explain its effect on metabolic enzymes to further clarify whether it will produce therapeutic drugs Influence. Doxofylline (DOXO), as an old drug that has been used for many years, has extremely high safety and strong selectivity. It is a clinical drug with an injectable dosage form. Studies have proved that DOXO can be used as a high-quality P450 mixed-function oxidase CYP1A in vivo probe. DOXO is a metabolic clearance-leading drug in the human body, and it must undergo the initiation metabolism of CYP1A in the cell to be transformed into theophylline acetaldehyde ( TA), and then theophylline acetic acid (TAA) and hydroxyethyl theophylline (ETO) produced by disproportionation. Therefore, quantitative detection of TAA and ETO can calculate the maximum activity of CYP1A. In order to study the kinetics of DOXO and reduce the inconvenience of excessive blood sampling points for long-term continuous administration, we will explore the method of detecting DOXO kinetics by the Vmax method through clinical research to characterize whether acupuncture affects the metabolic enzyme CYP1A


Description:

In the face of complex medical challenges, diversified medications, combination medications, compound medications, and precision medications have shown a clear upward trend. Quantitative monitoring of drugs in the body has gradually become a routine. However, this conventional method not only has a lag in time, but also has a scientific principle. There are also serious defects in nature. Time lag is manifested as a lack of predictability and individual differences over time. In principle, drug changes are the result of the body's reaction to drugs.Therefore, the body characteristics related to drug metabolism need to be evaluated first. The current therapeutic drug monitoring is almost lack of theoretical support. From the perspective of safety and mechanism-based pharmacokinetics, its specific manifestations are as follows: 1. Considering the individual safety, although there is the information support of group medicine, the drug dose must also be tested from a small dose; 2. The plasma drug concentration must be completed by multi-point continuous overall kinetic process test or obtained by model derivation, such as in vitro derivation based on enzymatic Michaelis kinetic parameters; 3. Single point plasma concentration can not replace the overall kinetic model. If necessary, there must be many assumptions and conditions. Therefore, the steady-state single point therapeutic drug monitoring (TDM) test obviously does not have the above three functions. Its data is unreasonably amplified to guide the accurate clinical administration, which will inevitably lead to many defects existing in principle, that is, "single point TDM" In principle, it can not cope with such a complex clinical treatment shared by multiple drugs and the prediction of drug-drug interaction (DDI). In vivo probe is an effective method to evaluate the influence of the body on the attribute law of drugs in vivo. Only based on the effective discrimination of the attribute law of drugs in vivo, can we obtain a complete prediction of the change law of a specific drug, and turn the passive technical method of blood concentration detection into initiative. DOXO is a metabolism-oriented drug, which is metabolized by CYP1A to TA, which further metabolizes TAA and ETO, so the amount of TAA and ETO can represent the activity of CYP1A, We will explore the method of detecting DOXO kinetics by Vmax method through clinical research. The entire clinical study is divided into two stages, the first stage is the solution of Vmax, and the second stage is the verification of the overall pharmacokinetics. Clinically, multi-drug combination is very easy to produce DDI, and the production of DDI is nothing more than pharmacodynamics or pharmacokinetic interactions. Therefore, when combining drugs or applying acupuncture and drug combination, it is also necessary to monitor the effects and effects of metabolic enzymes in the body on the drugs, and then to determine the safety and the mechanism of the effect of multi-drug sharing. Therefore, further explore acupuncture. Combined with the pharmacokinetic law of DOXO to explore the mechanism of the combined action of acupuncture and medicine.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date November 15, 2023
Est. primary completion date September 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Patients with pneumothorax or three and three lower rib fractures. 2. Age =18 years old and =40 years old, no gender limit; 3. No chronic underlying disease, no new onset or acute disease; 4. No long-term drug use history; 5. Understand and agree to participate in this study and sign an informed consent form. Exclusion Criteria: 1. Patients who have received EA treatment in the past; 2. Patients with skin infections in the local meridian points; 3. Patients with upper or lower limb nerve injury; 4. Those who have consumed tea, coffee, chocolate and smoked one week before the start of the test; 5. Those suffering from respiratory diseases, hyperthyroidism, sinus tachycardia, and arrhythmia; 6. Patients with severe heart, lung, liver, and kidney function abnormalities, patients with hypertension, patients with active gastric and duodenal ulcers or patients with co-infection; 7. Those who have participated in or are participating in other clinical trials one month before enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DOXO+electroacupuncture
DOXO+electroacupuncture

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Yueyang Integrated Medicine Hospital Shanghai University of Traditional Chinese Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary The concentration of DOXO and metabolites The concentrations of DOXO and its metabolites TA, TAA and ETO in blood were detected by LC-MS Within ten minutes after the start of administration
See also
  Status Clinical Trial Phase
Completed NCT03391986 - Acupuncture for Pain Management During Uterine Aspiration N/A
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Active, not recruiting NCT06070090 - Tapping in Together: A Pilot Study on Group Acupuncture for Ketamine Experience Integration N/A
Completed NCT03627533 - The Differences of Oocyte Maturation, Granulosa Cell Apoptosis Index Between Electroacupuncture And Sham Groups IVF N/A
Not yet recruiting NCT05794633 - Acupuncture Therapy in Patients With Subacromial Impingement Syndrome N/A
Recruiting NCT06001112 - Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis N/A
Completed NCT04844710 - The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms N/A
Active, not recruiting NCT04048941 - One Needle Hand Acupuncture for MSK Disorders N/A
Completed NCT04759079 - The Effects of Acupuncture Against Postoperative Nausea and Vomit After Laparoscopic Cholecystectomy N/A
Completed NCT03299439 - Acupuncture Treatment for Knee Osteoarthritis With Sensitive Acupoints and Tender Points N/A
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Completed NCT03008668 - A Pilot Trial of Acupuncture for Knee Osteoarthritis With Differential Functional Status of Acupoints N/A
Completed NCT01283477 - Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery N/A
Recruiting NCT06042465 - Investigation on Efficacy Between TCM Treatment Using Acupuncture and Tui-na With Physiotherapy on Patellofemoral Pain Syndrome N/A
Recruiting NCT05516862 - Determining the Right Acupuncture for Good Recovery Over Neuropsychiatric Trauma N/A
Completed NCT03633097 - Efficacy and Safety of Acupuncture Treatment as an Adjunctive Therapy After Knee Replacement N/A
Active, not recruiting NCT05938660 - Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students. N/A
Not yet recruiting NCT02597530 - Different Stimuli of Transcutaneous Electric Acupoint Stimulation(TEAS) on Acupuncture Anesthesia N/A
Recruiting NCT04249921 - Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base
Recruiting NCT05521737 - Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy N/A